



Published in final edited form as:

Pharmacol Ther. 2023 May ; 245: 108395. doi:10.1016/j.pharmthera.2023.108395.

Molecular Basis of Unique Specificity and Regulation of Group VIA Calcium-Independent Phospholipase A₂ (PNPLA9) and Its Role in Neurodegenerative Diseases

Daiki Hayashi^{1,*}, Edward A. Dennis²

¹Department of Applied Chemistry in Bioscience, Graduate School of Agricultural Science, Faculty of Agriculture, Kobe University, Kobe 657-8501, Japan

²Department of Pharmacology and Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, California 92093-0601, USA

Abstract

Glycerophospholipids are major components of cell membranes and consist of a glycerol backbone esterified with one of over 30 unique fatty acids at each of the *sn*-1 and *sn*-2 positions. In addition, in some human cells and tissues as much as 20% of the glycerophospholipids contain a fatty alcohol rather than an ester in the *sn*-1 position, although it can also occur in the *sn*-2 position. The *sn*-3 position of the glycerol backbone contains a phosphodiester bond linked to one of more than 10 unique polar head-groups. Hence, humans contain thousands of unique individual molecular species of phospholipids given the heterogeneity of the *sn*-1 and *sn*-2 linkage and carbon chains and the *sn*-3 polar groups. Phospholipase A₂ (PLA₂) is a superfamily of enzymes that hydrolyze the *sn*-2 fatty acyl chain resulting in lyso-phospholipids and free fatty acids that then undergo further metabolism. PLA₂'s play a critical role in lipid-mediated biological responses and membrane phospholipid remodeling. Among the PLA₂ enzymes, the Group VIA calcium-independent PLA₂ (GVIA iPLA₂), also referred to as PNPLA9, is a fascinating enzyme with broad substrate specificity and it is implicated in a wide variety of diseases. Especially notable, the GVIA iPLA₂ is implicated in the sequelae of several neurodegenerative diseases termed “phospholipase A₂-associated neurodegeneration” (PLAN) diseases. Despite many reports on the physiological role of the GVIA iPLA₂, the molecular basis of its enzymatic specificity was unclear. Recently, we employed state-of-the-art lipidomics and molecular dynamics techniques to elucidate the detailed molecular basis of its substrate specificity and regulation. In this review, we summarize the molecular basis of the enzymatic action of GVIA iPLA₂ and provide a perspective on future therapeutic strategies for PLAN diseases targeting GVIA iPLA₂.

*Corresponding author: Daiki Hayashi, Address: 1-1 Rokkodai, Nada, Kobe, Hyogo 657-8501, Japan, Phone: +81-78-803-5855, dhayashi@port.kobe-u.ac.jp.

Conflict of interest statement: The authors declare that there are no conflicts of interest.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Keywords

phospholipase A₂; GVIA iPLA₂; PLA₂G6; iPLA₂β; PNPLA9; neurodegeneration; neurodegenerative diseases

1. Introduction

Glycerophospholipids are major components of cell membranes and primarily function to partition cells and sub-cellular organelles, but they can also be a ready source of substrate for a variety of metabolic enzymes. Glycerophospholipids are composed of a glycerol backbone esterified with fatty acyl chains on its *sn*-1 and *sn*-2 positions and a phosphate group on the *sn*-3 position forming phosphatidic acid. Several head groups including choline, ethanolamine, serine, glycerol, inositol, and various inositol phosphates are esterified at the *sn*-3 phosphate forming polar head groups. Furthermore, in addition to the variation of acyl chains and head groups, the actual linkage at the *sn*-1 acyl chain can be an alkyl ether or a vinyl ether rather than an acyl group (Figure 1). Saturated and monounsaturated fatty acids are preferentially esterified at the *sn*-1 position, and *sn*-2 positions are rich in polyunsaturated fatty acids (PUFAs) (Yamashita et al., 2014). The characteristics and functions of the glycerophospholipids vary depending on the specific combination of acyl chains and head groups. Many 1,000's of unique molecular species are formed in mammals.

Phospholipase A₂ (PLA₂) is a superfamily of enzymes that hydrolyze glycerophospholipids at the *sn*-2 position and produces *sn*-2 lysophospholipids and free fatty acids (Dennis et al., 2011) (Figure 1). Lysophospholipids function as lipid mediators and are involved in numerous biological activities acting on a large variety of lysophospholipid receptors (Takagi et al., 2022; Tan et al., 2020). The free fatty acids, especially PUFAs, that are generated are further metabolized into various bioactive lipid mediators, often referred to as oxylipins, responsible for inflammation and resolution (Buczynski et al., 2009; Dennis & Norris, 2015; Funk, 2001; Serhan, 2007). Also, PLA₂ is a key enzyme, along with various lysophospholipid acyltransferases (LPLAT), that contributes to the Lands' cycle to maintain the homeostasis and diversity of the *sn*-2 acyl chain composition of membrane glycerophospholipids (Lands, 1957; Pérez-Chacón et al., 2009; Shindou & Shimizu, 2009). Therefore, PLA₂s play a central role in lipid-mediated biological activities and membrane glycerophospholipid remodeling and are involved in numerous diseases (Dennis et al., 2011).

The PLA₂ superfamily is comprised of six main types of enzymes and each possesses distinct structural features (Dennis et al., 2011). The secreted PLA₂s (sPLA₂s), the biggest category of the PLA₂ superfamily, is now composed of a number of groups (Group I, II, III, V, IX, X, XI, XII, XIII, and XIV) and subgroups. They have been extensively characterized and studied in various snake and bee venoms as well as in a variety of mammalian and human tissues (Murakami et al., 2015). sPLA₂s are small enzymes with a molecular mass of less than 20 kDa, requiring mM Ca²⁺ for their catalytic activity and mainly function extracellularly. Group IV cytosolic PLA₂s (GIV cPLA₂s) are intracellular cytosolic enzymes

containing calcium-binding C2 domains except for one subgroup of GIV cPLA₂ (GIVC cPLA₂, cPLA₂γ) (Leslie, 2015). Group VI calcium-independent PLA₂s (GVI PLA₂s), also known as the patatin-like phospholipase (PNPLA) family, are intracellular enzymes sharing the patatin domain found in a potato protein that has lipase activity (Kienesberger et al., 2009). Platelet-activating factor acetyl hydrolases (PAF-AHs) are named for their hydrolytic activity toward PAF, but also have been named as Lipoprotein-associated PLA₂ (Lp-PLA₂) for their activity toward oxidized phospholipids found extensively in lipoproteins, and these enzymes are categorized as Group VII and VIII PLA₂s (Kono & Arai, 2019). Lysosomal PLA₂ (LPLA₂, GXV PLA₂) is characterized by its localization in the lysosome and late endosome and is active under acidic conditions (Shayman & Tesmer, 2019). Adipose-specific PLA₂ (AdPLA₂, GXVI PLA₂) is a membrane-associated enzyme specifically expressed in white adipose tissue (Duncan et al., 2008). All PLA₂ enzymes discovered to date that have Group or Subgroup designations have been assigned to one of these six types based on their structural characteristics. Thus, the PLA₂ superfamily is composed of more than fifty unique enzymes (Dennis et al., 2011). Note that some enzymes possess no hydrolytic activity toward the *sn*-2 position of glycerophospholipids (PLA₂ activity) despite their name. Also, some enzymes exhibit PLA₁, lysophospholipase, triacylglycerol lipase, or transacylase activities. These unique enzymes play a central role in lipid metabolism and contribute to numerous biological events based on their tissue expression, subcellular localization, post-transcriptional regulation, and substrate specificity. Also, note that there are other enzymes that express PLA₂ activity besides those classified as being part of the PLA₂ superfamily, such as the α/β hydrolase domain (ABHD) proteins that possess a GX SXG lipase consensus motif (Lord et al., 2013; Murakami, 2017, 2019).

A subgroup of GVI iPLA₂ (GVIA iPLA₂, also referred to as PLA2G6, iPLA₂β, and PNPLA9) is a versatile PLA₂ enzyme involved in various diseases including diabetes, cancer, and various neurodegenerative diseases (Ramanadham et al., 2015). Despite its physiological role, its structure, regulation, and substrate specificity have not been well described. Recently, state-of-the-art techniques have enabled us to elucidate the molecular basis of the enzymatic action of GVIA iPLA₂. This review summarizes recent progress in understanding its structure, regulation, substrate specificity, and role in neurodegenerative diseases.

2. Structure and characteristics of GVIA iPLA₂

GVIA iPLA₂ is one of the PLA₂ enzymes that utilizes a Ser/Asp catalytic dyad for its hydrolysis reaction, as does its plant homolog patatin (Rydel et al., 2003). Also, GVIA iPLA₂ possesses not only PLA₂ activity but also acyl-CoA thioesterase (Carper et al., 2008; Jenkins et al., 2006), lysophospholipase, and transacylase activity (Lio & Dennis, 1998). Human GVIA iPLA₂ is encoded by the *PLA2G6* gene on chromosome 22q13.1 with 16 exons. *PLA2G6* produces several products by alternative splicing, and at least two are enzymatically active proteins. GVIA-1 iPLA₂ was first cloned as a 752 amino acid protein with a molecular mass of 85 kDa including eight ankyrin repeats at the N terminus of the catalytic domain and containing the GXS⁴⁶⁵XG lipase consensus sequence originally identified in the mouse enzyme (Ackermann et al., 1994; Tang et al., 1997). However, this variant was not a full-length protein in humans. In 1998, a longer isoform, an 806 amino

acid protein with a molecular mass of 88 kDa, was identified in human cells as a product of alternative splicing and named GVIA-2 iPLA₂ (Larsson et al., 1998; Ma et al., 1999). GVIA-2 iPLA₂ contains a 54 amino acid proline-rich insertion from exon 8 disrupting the eighth ankyrin repeat resulting in a longer linker region between the seventh ankyrin repeat and the lipase domain (Fig. 2A) (Ma et al., 1999). Both the long and short variants of GVIA iPLA₂ are found in human and rat cells in a tissue-dependent manner (Larsson Forsell et al., 1999; Ma et al., 1999; Winstead et al., 2000). However, GVIA-1 iPLA₂ seems to be the only active variant in hamster and mouse cells (Winstead et al., 2000). It was reported that both variants are Ca²⁺-independent enzymes and function as oligomers (Ma et al., 1999). However, the enzymatic activity of the long variant is upregulated by ATP, whereas the short variant is not (Ma et al., 1999). Since it has been suggested that the ankyrin repeat is important for oligomer formation of the GVIA iPLA₂ (Tang et al., 1997), the 54 amino acid insertion may affect its oligomer formation and function. Still, the details have not been well described. Also, it has been suggested that the 54 amino acid insertion induces the membrane localization of GVIA iPLA₂ (Larsson Forsell et al., 1999).

In addition to these two enzymatically active variants, several inactive variants have been identified. GVIA Ankyrin-1 and -2 (GVIA Ank-1 and -2) are products of the *PLA2G6* gene, but they are enzymatically inactive due to the termination of translation before the lipase domain (Larsson et al., 1998). GVIA Ank-1 shares the same amino acid sequence from residue 1 to 476 with GVIA-2 iPLA₂, which contains the 54 amino acid insertion and is terminated at residue 479. On the other hand, GVIA Ank-2 lacks residues 70 to 143 of the GVIA Ank-1 due to skipping of the second exon and an altered C-terminal 50 amino acids, resulting in a protein of 427 amino acids (Fig. 2A). These variants are enzymatically inactive, but it was reported that they suppress the activity of GVIA iPLA₂ by forming a hetero-dimer, suggesting that the ankyrin repeats of GVIA iPLA₂ contribute to its oligomerization (Larsson et al., 1998). In 2018, the X-ray crystal structure of GVIA-1 iPLA₂ was solved, although several residues were lacking, but it revealed that the GVIA iPLA₂ forms a homo dimer through their catalytic domains (Fig. 2B) (Malley et al., 2018). Also, the crystal structure identified an additional ankyrin repeat with a less conserved signature sequence (Fig. 2A). These findings suggested that the GVIA iPLA₂ homo dimer forms a hetero oligomer through another coupling protein binding to ankyrin repeats; still further investigation is needed to more precisely define the oligomerization state of active GVIA iPLA₂. It was reported that recombinant GVIA iPLA₂ protein lacking ankyrin repeats is inactive (Larsson et al., 1998). Therefore, although understanding just how ankyrin repeats function is poorly understood, ankyrin repeats are clearly critical for proper GVIA iPLA₂ function.

GVIA iPLA₂ is predominantly localized in the cytosol (Gross et al., 1993). Still, it has been reported that GVIA iPLA₂ shows multiple subcellular localizations including plasma membrane, endoplasmic reticulum (ER), mitochondria, Golgi, and the nucleus, depending on the cell type and stimulation (Bao et al., 2004; Chiu et al., 2017; Ramanadham et al., 2004; Song, Bao, et al., 2010). The membrane-binding region of the lipase domain of GVIA iPLA₂ was identified by hydrogen/deuterium exchange mass spectrometry (HDX-MS) and molecular dynamics (MD) simulations (Bucher et al., 2013; Hsu et al., 2009). These studies showed that the membrane anchoring region formed an amphipathic helix

(residues 710 to 724) which penetrates the surface of the lipid bilayer (Fig. 2C) (Bucher et al., 2013). Furthermore, the MD simulation suggested that the membrane anchoring region also functioned as a lid covering the active site of GVIA iPLA₂ in the absence of membrane, which upon membrane association undergoes a conformational change, contributing to the allosteric effect of the membrane (Bucher et al., 2013; Mouchlis & Dennis, 2022).

It is worth mentioning that the crystal structure failed to elucidate details of the membrane anchoring region, indicating the flexibility of the region (Malley et al., 2018). Although the membrane binding region was proposed, the membrane binding region itself does not fully explain the complex localization of GVIA iPLA₂. Although the detailed mechanisms of how intracellular localization of GVIA iPLA₂ is regulated are still enigmatic, caspase-3 cleavage of GVIA iPLA₂ at the N-terminal cleavage site in ankyrin repeats (¹⁸⁰DVTD¹⁸³) induces nucleus association (Ramanadham et al., 2004). Also, it has been reported that GVIA iPLA₂ interacts with the ER chaperone calnexin, and the interaction might be through ankyrin repeats (Malley et al., 2018; Song, Rohrs, et al., 2010). These observations indicate that the ankyrin repeats have an essential role in the regulation of subcellular localization of GVIA iPLA₂. Indeed, our preliminary data shows that GVIA iPLA₂ ankyrin repeat domains that are lacking the lipase domain shows specific subcellular localization. The underlying mechanism of the unique regulation of the subcellular localization needs further investigation.

3. Regulation of GVIA iPLA₂

GVIA iPLA₂ is expressed ubiquitously in humans. It was reported that the *PLA2G6* gene is regulated by the sterol regulatory element binding protein-1 (SREBP-1) through its sterol regulatory element (Lei et al., 2010). In addition, it has been suggested that a transcription factor ELK1 binds to the promoter region of the *PLA2G6* gene and may regulate its expression according to a database search, although experimental evidence is lacking (Matys et al., 2006; W. Y. Sun et al., 2021). Other than that, the promoter region of the *PLA2G6* gene contains a region homologous to the consensus sequence of several transcriptional factors. Therefore, gene expression of *PLA2G6* might be exquisitely regulated by multiple factors. Although studies on transcriptional regulation of GVIA iPLA₂ have not progressed far, understanding the regulation would be helpful in controlling the expression of GVIA iPLA₂ to treat related diseases.

GVIA iPLA₂ binds ATP, and its enzymatic activity is upregulated or protected by ATP in a phosphorylation-independent manner (Ackermann et al., 1994). It has been suggested that ATP increases the thermodynamic stability of the enzyme preventing inactivation since the effect of ATP on the GVIA-1 iPLA₂ activity is almost completely compensated for by adding 10% glycerol to stabilize the enzyme *in vitro* (Lio & Dennis, 1998). Later, it was reported that ATP protects the inactivation of GVIA-1 iPLA₂ by oxidation of cysteine (Song et al., 2006). The authors showed that ATP and dithiothreitol (DTT) prevent disulfide bond formations leading to inactivation at 37°C. However, since DTT could not completely compensate for the effect of ATP, the authors argued that ATP prevents loss of activity by undefined mechanisms. ATP might also stabilize GVIA-2 iPLA₂, but the stabilization cannot fully explain the effect of ATP on GVIA-2 iPLA₂ (Lio & Dennis, 1998;

Ma et al., 1999), suggesting that ATP can be an activator for GVIA-2 iPLA₂ somehow. GVIA-1 and -2 iPLA₂ possess consensus residues for a nucleotide-binding motif GXGXXG (⁴⁸⁵GGGVKG⁴⁹⁰ for GVIA-2 iPLA₂) found in protein kinases in the lipase domain (Hanks et al., 1988). Therefore, it has been thought that ATP binds to the region. However, Malley *et al.* reported that ATP interacts with the ankyrin repeat domain of GVI iPLA₂ (sixth ankyrin repeat) by co-crystallization with ATP, although its resolution was insufficient to show the detailed binding mode (Malley et al., 2018). Investigating the detailed ATP binding mode has the potential of revealing novel insights into understanding its activation mechanisms and help develop activators of GVIA iPLA₂.

Despite GVIA iPLA₂ activity being independent of Ca²⁺, Ca²⁺-activated calmodulin (CaM) has been proposed to inhibit its activity by direct binding of calmodulin to GVIA iPLA₂ (Wolf & Gross, 1996). It has been suggested that GVIA iPLA₂ interacts with CaM through CaM binding motifs such as the 1-9-14 motif (⁶⁷⁶IRKGQANKVKKLSI⁶⁸⁹ for GVIA-2 iPLA₂) and IQ motif (⁷⁵⁵IQYFRLNPQLGTDI⁷⁶⁸ for GVIA-2 iPLA₂) which reside in the lipase domain (Fig. 2A, C) (Jenkins et al., 2001). Recently, it was shown that CaM most likely binds to the 1-9-14 motif, not to the IQ motif, and dimer formation is critical for CaM binding to GVIA iPLA₂ using a fluorescent polarization assay (Malley et al., 2018). Also, it has been reported that GVIA iPLA₂ forms a signaling complex with calcium/calmodulin-dependent kinase IIβ (CaMKIIβ) (Wang et al., 2005).

It is known that GVIA iPLA₂ is regulated by caspase-3 cleavage via several cleavage sites. As described earlier, GVIA iPLA₂ is processed into a 63 kDa isoform by caspase-3 at the N-terminal cleavage site and is activated and accumulated at the nucleus, presumably destroying the nuclear membrane upon apoptosis (Ramanadham et al., 2004). In addition, a 70 kDa GVIA iPLA₂ truncated at the C-terminal was found in INS-1 insulinoma cells and specifically participated in insulin secretion (Ramanadham et al., 2003). However, the detailed description of truncated GVIA iPLA₂s is lacking in other than pancreatic cells.

4. Substrate specificity of GVIA iPLA₂

When the murine GVIA iPLA₂ was purified and cloned, *in vitro* substrate specificity toward the *sn*-2 acyl chain was investigated (Ackermann et al., 1994; Tang et al., 1997). These later papers independently reported that GVIA iPLA₂ showed higher activity toward *sn*-2 palmitic acid (16:0) over arachidonic acid (AA, 20:4) in contrast to cPLA₂, which is highly selective for the *sn*-2 AA chain (Clark et al., 1991). Furthermore, Tang *et al.* reported that *sn*-2 linoleic acid (18:2) and oleic acid (18:1) are better substrates for GVIA iPLA₂ than AA (Tang et al., 1997). Also, they reported that GVIA iPLA₂ showed remarkably higher activity toward the phospholipid with a head group of PA than PC. However, the limitation of available pure glycerophospholipid species and the activity detection methods at the time which included radioactivity and colorimetric methods, prevented determining the detailed *in vitro* substrate specificity of GVIA iPLA₂.

The recent evolution of lipid synthetic methodology has resulted in the commercial availability of pure phospholipid molecular species standards and the development of mass spectrometry based lipidomics has enabled us to investigate the detailed *in vitro*

substrate specificity of PLA₂ enzymes toward at least all the major molecular species of glycerophospholipids. In 2018, a lipidomics-based *in vitro* PLA₂ activity assay using HPLC-MS/MS was developed (Mouchlis et al., 2018). The assay can evaluate PLA₂ activity by quantifying the lysophospholipid products of PLA₂ activity toward mixed micelles containing specific glycerophospholipids and the nonionic surfactant (octaethylene glycol monododecyl ether, C₁₂E₈). The substrate specificity of the GVIA-2 iPLA₂ toward PC containing myristic acid (14:0), 16:0, stearic acid (18:0), 18:1, 18:2, 20:4, and docosahexaenoic acid (DHA, 22:6) on the *sn*-2 position was investigated using this assay.

It was found that phospholipids containing *sn*-2 14:0 and 18:2 were the optimum substrates for the human recombinant GVIA-2 iPLA₂ (Mouchlis et al., 2018). To explain this unique *sn*-2 acyl chain specificity, all-atom MD simulations were carried out using a complex of each substrate and the lipase domain of the GVIA iPLA₂. The substrates were docked in the active site based on the optimal binding observed in earlier simulations (Mouchlis et al., 2015). The MD simulations suggested that GVIA iPLA₂ utilizes two alternative hydrophobic sub-pockets to accommodate the *sn*-2 acyl chain; one is composed of aliphatic hydrophobic residues such as Leu491, Ile494, Ile523, Leu524, Leu564, Met537, and Leu560 suitable for accommodating short saturated acyl chains like 14:0; the other site contained aromatic residues such as Tyr541, Tyr555, and Phe644 that can interact with double bonds in the acyl chain via pi-pi stacking and is suitable for unsaturated acyl chains like 18:2 (Fig. 3A) (Mouchlis et al., 2018). Furthermore, the study revealed that GVIA-2 iPLA₂ slightly prefers the head group of PE in the equal molar mixture of major head groups (PC, PE, PS, PG, PA), although the preference was mild.

Thereafter, the more detailed substrate specificity of GVIA-2 iPLA₂ was investigated using the same method especially focusing on AA, eicosapentaenoic acid (EPA, 20:5), and DHA precursors of various bioactive oxylipins (Dennis & Norris, 2015; Willenberg et al., 2015). In the study, we reported that GVIA-2 iPLA₂ shows significantly higher activity toward *sn*-2 EPA among AA, EPA, and DHA containing PE even in a mixture of phospholipids containing various *sn*-2 acyl chains and that activity toward EPA was comparable to that toward 18:2 (Fig. 3B) (Hayashi et al., 2021). Furthermore, MD-simulations revealed that, in contrast to the case of 14:0 and 18:2, GVIA iPLA₂ significantly and stably accommodated EPA in the shallow hydrophobic cavity by adopting both aliphatic and aromatic residues to form a hydrophobic environment fitting the curvature of the EPA chain (Fig. 3C). In contrast, we suggested that hydrophobic subsites for the *sn*-2 acyl chains seemed not to be able to easily retain a DHA chain due to its additional two carbons. This series of studies revealed the detailed *in vitro* substrate specificity of GVIA iPLA₂ toward various major glycerophospholipids. We concluded that the geometry of the hydrophobic pocket contributes to the binding pose of the ligands and confers the unique substrate specificity on the GVIA iPLA₂ (Hayashi et al., 2021; Mouchlis et al., 2015, 2018). Furthermore, an *ex vivo* study using rat hearts and PLA₂ inhibitors recently reported that GVIA iPLA₂ preferentially releases EPA rather than DHA (Manson et al., 2023). This indicates that the *in vitro* specificity and the molecular dynamics features of GVIA iPLA₂ have relevance to its *in vivo* functions.

As shown in Fig. 1, glycerophospholipids can possess alkyl ether linkages or vinyl ether linkages instead of an ester linkage in their *sn*-1 position, and this affects the biological activities (Dean & Lodhi, 2018). The former is a precursor to PAF (1-*O*-Hexadecyl-2-*O*-acetyl-*sn*-glycero-3-phosphocholine) when the *sn*-2 chain is converted to an acetyl group. The latter exists ubiquitously as a component of cell membranes and contributes to the formation of lipid raft microdomains (Pike et al., 2002; Rodemer et al., 2003), membrane trafficking, and cell differentiation (Dean & Lodhi, 2018; Hossain et al., 2016; Komljenovic et al., 2009; Teigler et al., 2009; Tsukahara et al., 2006).

We have investigated the effect of the *sn*-1 acyl chain linkage using the *in vitro* assay and reported that GVIA-2 iPLA₂ showed lower activity toward *sn*-1 alkyl ether phospholipids compared to *sn*-1 ester and vinyl ether phospholipids by up to a factor of two (Fig. 3C) (Hayashi et al., 2022). However, no significant difference was observed between the activity toward ester and vinyl ether phospholipids. Detailed explanations for how the GVIA iPLA₂ distinguishes the *sn*-1 acyl chain linkage are unknown, but the previous MD simulation showed that Lys729 in the active site of GVIA iPLA₂ frequently interacts with the *sn*-1 acyl chain linkage (Fig. 3E). Therefore, the *sn*-1 acyl chain linkage is likely to contribute to the binding affinity of a substrate in the active site. Also, PLA₂ extracts a single substrate from the glycerophospholipid pool to hydrolyze the substrate (Mouchlis et al., 2015). MD simulations revealed how a single glycerophospholipid is pulled into GVIA iPLA₂ active site, and several residues interact with the *sn*-1 linkage upon the extraction (Fig. 3D). Therefore, although further investigation is needed to determine if and how the *sn*-1 acyl chain linkage might play a role in the substrate extraction by GVIA iPLA₂. Notably, the study also revealed that the *sn*-1 acyl chain linkage does not significantly affect the *sn*-2 acyl chain specificity and that the GVIA iPLA₂ prefers steric acid at the *sn*-1 position. Also, consistent with the previous report, the GVIA iPLA₂ possesses hydrolase activity toward PAF, although its activity was far lower than that toward longer *sn*-2 acyl chains (Hayashi et al., 2022; Tang et al., 1997).

Although the detailed *in vitro* substrate specificity of GVIA iPLA₂ has been clarified, sometimes there is a gap between *in vitro* specificity and observations in *in vivo* and *ex vivo* studies. DHA-containing glycerophospholipids are highly abundant in the brain (Brenna & Diau, 2007; C. T. Chen et al., 2009), and several studies reported that *PLA2G6* knockout mice show impaired DHA metabolism in the brain (Basselin et al., 2010; Beck et al., 2011; Cheon et al., 2012). However, *in vitro* specificity indicated that at least GVIA-2 iPLA₂ shows inferior activity toward DHA compared to AA and EPA in equivalent phospholipids (Hayashi et al., 2021; Mouchlis et al., 2018). Also, our *in vitro* study demonstrated that GVIA-2 iPLA₂ slightly prefers glycerophospholipids with 18:0 rather than 16:0 at the *sn*-1 position (Hayashi et al., 2022; Mouchlis et al., 2018). However, it has been demonstrated that GVIA iPLA₂ preferentially hydrolyzes glycerophospholipids which have 16:0 in the *sn*-1 position in certain cultured cells and *PLA2G6* knockout mice (Deng et al., 2016; Gil-de-Gómez et al., 2014; Murakami et al., 2005). Substrate availability might be one of the reasons for the gap between *in vitro* and *in vivo* observations. These studies suggested that GVIA iPLA₂ hydrolyzes these substrates somewhat, even if they are a poorer substrate for GVIA iPLA₂ *in vitro*, depending on substrate availability. Indeed, it was reported that GVIA iPLA₂ preferentially hydrolyzed plasmalogen over ester lipids as a source of AA in

certain cells upon thrombin stimulation; however, GVIA iPLA₂ utilized ester phospholipids in the plasmalogen-deficient cells without any changes in the AA release. (Beckett et al., 2007; Gaposchkin et al., 2008). Perhaps some unknown factors alter the substrate specificity of GVIA iPLA₂, such as interaction with other proteins, post-transcriptional modifications, and alternative splicing. So far, we have been focused on the *in vitro* specificity of the more abundant GVIA-2 iPLA₂. Thus, it may be worth investigating further the specificity of the GVIA-1 iPLA₂ or the caspase-3 cleaved forms in case they play larger roles in specific brain regions or sub-organelles. Of course, other PLA₂'s, such as sPLA₂'s may exist in brain and play a role in releasing DHA.

In summary, by taking advantage of new lipidomics and computational techniques, we have been able to establish the *in vitro* substrate specificity of the human Group VIA-2 iPLA₂ and its underlying molecular mechanism. However, some open questions remain. One is determining the activity of GVIA iPLA₂ toward the numerous PI monophosphate isomers as well as PIP₂ and PIP₃, for which the lipidomics-based PLA₂ assay will have to be modified in order to detect their more polar lysophospholipid products. Another is the specificity of GVIA iPLA₂ toward oxidized phospholipids. It has been reported that GVIA iPLA₂ expresses a protective role against oxidative stress by hydrolyzing the oxidized acyl chains (Cabo et al., 2006; Kinghorn et al., 2015). However, due to the lack of availability of pure substrates for the *in vitro* assay, the specificity and molecular interactions remain unclear. Furthermore, we previously showed that GVIA iPLA₂ can hydrolyze cardiolipins, which are important mitochondria-specific phospholipids whose metabolism is linked to the pathogenesis of Barth syndrome (Hsu et al., 2013; Malhotra et al., 2009). However, the detailed activity toward various cardiolipin molecular species and its binding modes in the active site have not been investigated.

5. Role of GVIA iPLA₂ in neurodegenerative diseases

GVIA iPLA₂ is expressed ubiquitously in humans, including the brain, and widely exists in different brain regions such as the hypothalamus, hippocampus, cerebral cortex, midbrain, and striatum (Molloy et al., 1998). Various neurodegenerative diseases that are believed to result from mutations in the *PLA2G6* gene have been reported, and now, they are recognized as *PLA2G6*-associated neurodegeneration (PLAN) diseases (Guo et al., 2018). PLAN diseases includes heterogeneity pathology and a phenotype in several neurodegeneration diseases including infantile neuroaxonal dystrophy (INAD), atypical neuroaxonal dystrophy (ANAD), and adult-onset dystonia-parkinsonism (DP). INAD appears during the first 6 months to 3 years of life and rapidly progresses to neurodegenerative disease characterized by brain iron accumulation. In contrast, ANAD appears in early childhood to the juvenile phase, and is also characterized by brain iron accumulation. DP is an adult-onset neurodegenerative disease which appears between 20 to 40 years of age. The PLAN-related mutated regions are widespread in the GVIA iPLA₂, including in the ankyrin repeats, and the specific mutation affects the specific symptoms and age of onset (Guo et al., 2018; Morgan et al., 2006; Paisan-Ruiz et al., 2009). Also, mutations of the *PLA2G6* gene are recognized as a critical risk factor for Parkinson's disease and identified as a disease locus PARK14 (Paisan-Ruiz et al., 2009; Tomiyama et al., 2011; Yoshino et al., 2010).

In 2006, Morgan *et al.* identified 44 unique mutations, including 32 missense mutations in the *PLA2G6* gene from patients with INAD and neurodegeneration with brain iron accumulation (NBIA) (Morgan *et al.*, 2006). The mutations were widely spread along the sequence of the GVIA iPLA₂, including in the ankyrin repeat and the catalytic domain as well as in a 54 amino acid insertion in GVIA-2 iPLA₂. Since these mutations were found in both INAD and NBIA, mutations of *PLA2G6* have been thought to result in childhood onset of neurodegenerative diseases. In 2009, two individual missense mutations in the *PLA2G6* gene were discovered in patients with adult-onset DP (Paisan-Ruiz *et al.*, 2009; Sina *et al.*, 2009). Since then, considerable attention has been paid to the *PLA2G6* gene in the adult onset of neurodegenerative diseases in addition to those with childhood-onset, such as INAD and ANAD. Many of these mutations are likely to result in a loss of activity. Indeed, systemic *PLA2G6* null and mutated mice show neurodegenerative phenotypes with degeneration of axons and dendrites in neuronal cells (Malik *et al.*, 2008; Shinzawa *et al.*, 2008; Wada *et al.*, 2009). However, it is still an open question as to why *PLA2G6* mutations correlate with the pathology and phenotype of neurodegeneration diseases. Interestingly, some of the mutations found in DP, such as R741W, were also found in INAD patients (Morgan *et al.*, 2006; Paisan-Ruiz *et al.*, 2009).

In mice studies, although the mutated GVIA iPLA₂ expressed in the mice show null PLA₂ activity, the phenotype and the age of onset were different from that of GVIA iPLA₂ protein null mice (Malik *et al.*, 2008; Shinzawa *et al.*, 2008; Wada *et al.*, 2009), suggesting that existence of inactive protein might also play a role in the brain. Interestingly, it has been reported that some mutations of GVIA iPLA₂ found in patients with DP, R741Q, R747W, and R632W, showed comparable or higher PLA₂ and PLA₁ activity compared to the wild-type enzyme, but similar mutations found in patients with INAD did not (Engel *et al.*, 2010). Thus, a significant number of mutations of *PLA2G6* associated with various neurodegeneration diseases have been reported, but the role of each mutant in the pathogenesis and phenotype is still enigmatic.

GVIA iPLA₂ has been recognized as an enzyme responsible for membrane remodeling and maintaining membrane lipid homeostasis (Balsinde *et al.*, 1995, 1997). Therefore, the cause of PLAN has been thought to relate to membrane homeostasis (Malik *et al.*, 2008). As described earlier, GVIA iPLA₂ is a responsible enzyme for the metabolism of DHA in the brain (Basselín *et al.*, 2010; Beck *et al.*, 2011; Cheon *et al.*, 2012). Cheon *et al.* compared the lipid compositions in the brain of wild-type and *PLA2G6* knockout mice and reported that the knockout mice impair DHA metabolism in the brain (Cheon *et al.*, 2012). Also, it is known that DHA plays a critical role in neuronal cell survival and health (G. Y. Sun *et al.*, 2018). Therefore, loss of GVIA iPLA₂ function appears to cause various neurological disorders via impairment of DHA metabolism in the brain. Furthermore, these authors also reported a comprehensive comparison of the esterified fatty acid composition in the various lipid species in the brain and observed differences in the compositions. Therefore, the impairment of brain phospholipid composition is thought to be a cause of PLAN diseases. In addition, many functions of GVIA iPLA₂ related to the pathogenesis of PLAN have been reported so far.

It is well known that Lewy body formation is one of the key pathogenesis findings in Parkinson's disease, and Lewy body's are mainly formed with presynaptic protein α -synuclein (Deramecourt et al., 2006; Mahul-Mellier et al., 2020). Indeed, Lewy body accumulation in the brain from PLAN patients has been observed (Paisán-Ruiz et al., 2012). A study using *PLA2G6* knockout mice showed the expression level of α -synuclein increases in mitochondria and suggested that α -synuclein stabilizes mitochondrial membranes in *PLA2G6* deficient neurons (Beck et al., 2016). Further, a study in *Drosophila* revealed that GVIA iPLA₂ deficiency accelerates α -synuclein accumulation and that the accumulation was restored by oleic acid supplementation, which resulted in the normalization of brain lipid composition (Mori et al., 2019). These studies indicate that GVIA iPLA₂ plays a critical role in Lewy body formation through its membrane remodeling function.

More recently, it was reported that GVIA iPLA₂ prevents ferroptotic cell death, which is triggered by iron-dependent lipid peroxidation by hydrolyzing oxidized phospholipids, and that a *PLA2G6* mutation induces ferroptotic neuronal cell death leading to PLAN (D. Chen et al., 2021; W. Y. Sun et al., 2021). The authors reported that the R747W mutant, which relates to DP, attenuates the activity of GVIA iPLA₂ toward oxidized phospholipids such as 15-hydroperoxy-arachidonoyl-phosphatidylethanolamine without significant effect on the activity toward AA metabolism and promotes ferroptotic cell death leading to Parkinsonian phenotype (W. Y. Sun et al., 2021). Therefore, the activity of GVIA iPLA₂ toward oxidized phospholipids is involved in ferroptosis and is also critical in the pathogenesis of PLAN. Notably, the study shows for the first time that the mutation alters the substrate specificity of GVIA iPLA₂, although the mutation shows a minimal effect on the basal PLA₂ activity. The authors suggested by taking advantage of MD simulations that the R747W mutation reduces the accessibility of the substrates to the active site and the association with the membrane.

By taking advantage of the D331Y mutation, which resides in ankyrin repeats of GVIA iPLA₂, found in Asian patients with autosomal-recessive early-onset parkinsonism (AREP) (Lu et al., 2012; Shi et al., 2011), several studies reported the functions of GVIA iPLA₂ in the neurons. The D331Y mutant shows less than 50% of PLA₂ activity compared to a normal GVIA iPLA₂ (Chiu et al., 2019). Chiu *et al.* reported that D331Y knock-in mice exhibited mitochondrial dysfunction, mitophagy impairment, and ER stress (Chiu et al., 2019). Further, another group reported using patient-delivered induced pluripotent stem cells (iPSC) from dopaminergic neurons possessing a homozygous D331Y mutant that the cell exhibited similar PD-related cascade events, including ER stress as in the former report (Ke et al., 2020). In contrast, although this observation was in pancreatic β cells, GVIA iPLA₂ upregulates ER stress and apoptosis through the production of proinflammatory cytokines, and inhibition of GVIA iPLA₂ by a specific inhibitor prevents β cell death (Ali et al., 2013; Lei et al., 2014). This opposite role of GVIA iPLA₂ in ER stress can be attributed simply to the difference in cell type, but the details remain unclear. Since the mutation is in the ankyrin repeats near the putative ATP binding residues, the specific function of ankyrin repeats might contribute to the effect. Interestingly, it has been demonstrated that DHA supplements improved motor dysfunction of D331Y homozygous knock-in mice, suggesting DHA can be critical for the biological event related to the D331Y mutation (Yeh et al., 2021).

Among the GVI iPLA₂s, GVIB iPLA₂ (iPLA₂γ) is also known to be implicated in neurodegenerative diseases (Mancuso et al., 2009). It has been reported in animal studies that GVIB iPLA₂ is involved in mitochondrial lipid metabolism and increases and prevents mitochondrial lipid peroxidation similar to several mutations in the GVIA iPLA₂ (Chao et al., 2018; Mancuso et al., 2009). GVIB iPLA₂ is an enzyme that consists of 782 amino acids and possesses both PLA₂ and PLA₁ activity (Mancuso et al., 2000; Yan et al., 2005). Both GVIA and GVIB iPLA₂ are specifically inhibited by (*S*)- and (*R*)-bromo-enol lactone (BEL), respectively, and for each the specific optical isomer is critical to the inhibition (Jenkins et al., 2002). GVIB iPLA₂ lacks the ankyrin repeat domain, and the homology between GVIA and GVIB is low. However, it was observed in the AlphaFold-predicted structure of the GVIB iPLA₂ that the three-dimensional structure of the catalytic domain of GVIB iPLA₂ is well aligned with that of GVIA iPLA₂ (RMSD was 1.23) (Fig. 4) (Jumper et al., 2021; Varadi et al., 2022). Therefore, it is possible that GVIB iPLA₂ shares some functions and substrate specificity with the GVIA iPLA₂ although further structural and biochemical investigations are needed.

More than 100 unique pathogenic mutations on *PLA2G6* have been reported so far (Guo et al., 2018). However, many of the reports do not characterize the effect of the mutation on the GVIA iPLA₂ enzyme, and how they contribute to the pathogenesis. Therefore, further molecular and biochemical studies are needed in order to better understand the etiology and pathogenesis of PLAN.

6. Conclusions and future directions

We have reviewed the emerging evidence for a central role of GVIA iPLA₂ in several important neurodegenerative diseases (Fig. 5). However, despite the recent understanding of the physiological function of GVIA iPLA₂, and our new understanding of the mechanism of action and specificity of GVIA iPLA₂ at the molecular level, there is still much to learn about the function of GVIA iPLA₂. By taking advantage of new lipidomics and computational approaches, the detailed *in vitro* substrate specificity and the enzymes mechanism of action have been revealed, although there are still many details that require further investigation, such as iPLA₂ specificity toward oxidized phospholipids. With the solution of the crystal structure of GVIA-1 iPLA₂ in 2018, the understanding of iPLA₂ structural features should be accelerated and help further understanding of GVIA iPLA₂ function. Hopefully, the advances in the basic science underlying iPLA₂ action summarized here will lead to new understanding and therapeutic strategies to prevent and/or treat *PLA2G6*-associated diseases, including PLAN.

In particular, the normalization or up-regulation of GVIA iPLA₂ should be a straightforward and reasonable strategy to treat or prevent PLAN. By taking advantage of adeno-associated virus (AAV), the delivery of the normal *PLA2G6* gene was attempted, and it was reported that a single dose of AAV carrying the *PLA2G6* gene to *PLA2G6* associated INAD mice significantly improved life span and neuronal viability in the brain (Iankova et al., 2021; Whaler, 2018). Besides, the development of pharmacological chaperons or activators for GVIA iPLA₂ mutants can be attempted. Furthermore, computational approaches should be helpful in screening small molecules. However, activation and stabilization mechanisms

of GVIA iPLA₂ have not been well enough understood yet to design small molecules. Therapeutic advances of *PLA2G6*-associated diseases will clearly require further study on the detailed molecular mechanism and substrate specificity, and new strategies for activation/inactivation of GVIA iPLA₂ are needed.

Acknowledgement

Work on this manuscript was supported by NIGMS MIRA grant R35 GM139641, which is a renewal of RO1 GM20501-44 (E. A. D.), and by a postdoctoral fellowship from The Uehara Memorial Foundation (D.H.).

Abbreviations:

AA	arachidonic acid
ATP	adenosine triphosphate
CaM	calmodulin
DHA	docosahexaenoic acid
EPA	eicosapentaenoic acid
ER	endoplasmic reticulum
GVIA iPLA₂	Group VIA calcium-independent PLA ₂
PLA₂	phospholipase A ₂
PLAN	Phospholipase A ₂ -associated neurodegeneration
PUFAs	polyunsaturated fatty acids

References

- Ackermann EJ, Kempner ES, & Dennis EA (1994). Ca²⁺-independent cytosolic phospholipase A₂ from macrophage-like P388D1 cells. *Journal of Biological Chemistry*, 269(12), 9227–9233. [PubMed: 8132660]
- Ali T, Kokotos G, Magrioti V, Bone RN, Mobley JA, Hancock W, & Ramanadham S. (2013). Characterization of FKGG18 as Inhibitor of Group VIA Ca²⁺-Independent Phospholipase A₂ (iPLA₂β): Candidate Drug for Preventing Beta-Cell Apoptosis and Diabetes. *PLoS ONE*, 8(8). 10.1371/journal.pone.0071748
- Balsinde J, Balboa MA, & Dennis EA (1997). Antisense inhibition of group VI Ca²⁺-independent phospholipase A₂ blocks phospholipid fatty acid remodeling in murine P388D1 macrophages. *Journal of Biological Chemistry*, 272(46). 10.1074/jbc.272.46.29317
- Balsinde J, Bianco ID, Ackermann EJ, Conde-Frieboes K, & Dennis EA (1995). Inhibition of calcium-independent phospholipase A₂ prevents arachidonic acid incorporation and phospholipid remodeling in P388D1 macrophages. *Proceedings of the National Academy of Sciences of the United States of America*, 92(18). 10.1073/pnas.92.18.8527
- Bao S, Jin C, Zhang S, Turk J, Ma Z, & Ramanadham S. (2004). β-Cell Calcium-Independent Group VIA Phospholipase A₂ (iPLA₂ β): Tracking iPLA₂ β Movements in Response to Stimulation With Insulin Secretagogues in INS-1 Cells.
- Basselín M, Rosa AO, Ramadan E, Cheon Y, Chang L, Chen M, Greenstein D, Wohltmann M, Turk J, & Rapoport SI (2010). Imaging decreased brain docosahexaenoic acid metabolism and signaling in

- iPLA2 β (VIA)-deficient mice. *Journal of Lipid Research*, 51(11), 3166–3173. 10.1194/jlr.M008334 [PubMed: 20686114]
- Beck G, Sugiura Y, Shinzawa K, Kato S, Setou M, Tsujimoto Y, Sakoda S, & Sumi-Akamaru H. (2011). Neuroaxonal dystrophy in calcium-independent phospholipase A2 β deficiency results from insufficient remodeling and degeneration of mitochondrial and presynaptic membranes. *Journal of Neuroscience*, 31(31), 11411–11420. 10.1523/JNEUROSCI.0345-11.2011 [PubMed: 21813701]
- Beck G, Sumi-Akamaru H, Fujimura H, Yoshida M, Sakoda S, Shinzawa K, Kato S, Riku Y, Tsujimoto Y, & Mochizuki H. (2016). High expression of α -synuclein in damaged mitochondria with PLA2G6 dysfunction. *Acta Neuropathologica Communications*, 4(1), 1–16. 10.1186/s40478-016-0298-3 [PubMed: 26727948]
- Beckett CS, Kell PJ, Creer MH, & McHowat J. (2007). Phospholipase A2-catalyzed hydrolysis of plasmalogen phospholipids in thrombin-stimulated human platelets. *Thrombosis Research*, 120(2). 10.1016/j.thromres.2006.09.005
- Brenna JT, & Diau GY (2007). The influence of dietary docosahexaenoic acid and arachidonic acid on central nervous system polyunsaturated fatty acid composition. *Prostaglandins Leukotrienes and Essential Fatty Acids*, 77(5–6), 247–250. 10.1016/j.plefa.2007.10.016 [PubMed: 18023566]
- Bucher D, Hsu YH, Mouchlis VD, Dennis EA, & McCammon JA (2013). Insertion of the Ca²⁺-Independent Phospholipase A2 into a Phospholipid Bilayer via Coarse-Grained and Atomistic Molecular Dynamics Simulations. *PLoS Computational Biology*. 10.1371/journal.pcbi.1003156
- Buczynski MW, Dumlao DS, & Dennis EA (2009). An integrated omics analysis of eicosanoid biology. *Journal of Lipid Research*, 50(6), 1015–1038. 10.1194/jlr.R900004JLR200 [PubMed: 19244215]
- de Cabo R, Burgess JR, & Navas P. (2006). Adaptations to oxidative stress induced by vitamin E deficiency in rat liver. *Journal of Bioenergetics and Biomembranes*, 38(5–6). 10.1007/s10863-006-9050-1
- Carper MJ, Zhang S, Turk J, & Ramanadham S. (2008). Skeletal muscle group VIA phospholipase A2 (iPLA 2 β): Expression and role in fatty acid oxidation. *Biochemistry*, 47(46). 10.1021/bi800923s
- Chao H, Liu Y, Fu X, Xu X, Bao Z, Lin C, Li Z, Liu Y, Wang X, You Y, Liu N, & Ji J. (2018). Lowered iPLA2 γ activity causes increased mitochondrial lipid peroxidation and mitochondrial dysfunction in a rotenone-induced model of Parkinson's disease. *Experimental Neurology*, 300. 10.1016/j.expneurol.2017.10.031
- Chen CT, Liu Z, Ouellet M, Calon F, & Bazinet RP (2009). Rapid β -oxidation of eicosapentaenoic acid in mouse brain: An in situ study. *Prostaglandins Leukotrienes and Essential Fatty Acids*, 80(2–3), 157–163. 10.1016/j.plefa.2009.01.005 [PubMed: 19237271]
- Chen D, Chu B, Yang X, Liu Z, Jin Y, Kon N, Rabadan R, Jiang X, Stockwell BR, & Gu W. (2021). iPLA2 β -mediated lipid detoxification controls p53-driven ferroptosis independent of GPX4. *Nature Communications*, 12(1), 1–15. 10.1038/s41467-021-23902-6
- Cheon Y, Kim HW, Igarashi M, Modi HR, Chang L, Ma K, Greenstein D, Wohltmann M, Turk J, Rapoport SI, & Taha AY (2012). Disturbed brain phospholipid and docosahexaenoic acid metabolism in calcium-independent phospholipase A2-VIA (iPLA2 β)-knockout mice. *Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids*, 1821(9), 1278–1286. 10.1016/j.bbalip.2012.02.003
- Chiu CC, Lu CS, Weng YH, Chen YL, Huang YZ, Chen RS, Cheng YC, Huang YC, Liu YC, Lai SC, Lin KJ, Lin YW, Chen YJ, Chen CL, Yeh TH, & Wang HL (2019). PARK14 (D331Y) PLA2G6 Causes Early-Onset Degeneration of Substantia Nigra Dopaminergic Neurons by Inducing Mitochondrial Dysfunction, ER Stress, Mitophagy Impairment and Transcriptional Dysregulation in a Knockin Mouse Model. *Molecular Neurobiology*, 56(6), 3835–3853. 10.1007/s12035-018-1118-5 [PubMed: 30088174]
- Chiu CC, Yeh TH, Lu CS, Huang YC, Cheng YC, Huang YZ, Weng YH, Liu YC, Lai SC, Chen YL, Chen YJ, Chen CL, Chen HY, Lin YW, & Wang HL (2017). PARK14 PLA2G6 mutants are defective in preventing rotenone-induced mitochondrial dysfunction, ROS generation and activation of mitochondrial apoptotic pathway. *Oncotarget*, 8(45), 79046–79060. 10.18632/oncotarget.20893 [PubMed: 29108286]
- Clark JD, Lin LL, Kriz RW, Ramesha CS, Sultzman LA, Lin AY, Milona N, & Knopf JL (1991). A novel arachidonic acid-selective cytosolic PLA2 contains a Ca²⁺-dependent translocation

- domain with homology to PKC and GAP. *Cell*, 65(6), 1043–1051. 10.1016/0092-8674(91)90556-E [PubMed: 1904318]
- Dean JM, & Lodhi IJ (2018). Structural and functional roles of ether lipids. *Protein and Cell*, 9(2), 196–206. 10.1007/s13238-017-0423-5 [PubMed: 28523433]
- Deng X, Wang J, Jiao L, Utaipan T, Tuma-Kellner S, Schmitz G, Liebisch G, Stremmel W, & Chamulitrat W. (2016). IPLA2 β deficiency attenuates obesity and hepatic steatosis in ob/ob mice through hepatic fatty-acyl phospholipid remodeling. *Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids*, 1861(5), 449–461. 10.1016/j.bbalip.2016.02.004
- Dennis EA, Cao J, Hsu YH, Magrioti V, & Kokotos G. (2011). Phospholipase A2 enzymes: Physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. *Chemical Reviews*, 111(10), 6130–6185. 10.1021/cr200085w [PubMed: 21910409]
- Dennis EA, & Norris PC (2015). Eicosanoid storm in infection and inflammation. *Nature Reviews Immunology*, 15(8), 511–523. 10.1038/nri3859
- Deramecourt V, Bombois S, Muraige CA, Ghestem A, Drobecq H, Vanmechelen E, Lebert F, Pasquier F, & Delacourte A. (2006). Biochemical staging of synucleinopathy and amyloid deposition in dementia with Lewy bodies. *Journal of Neuropathology and Experimental Neurology*, 65(3). 10.1097/01.jnen.0000205145.54457.ea
- Duncan RE, Sarkadi-Nagy E, Jaworski K, Ahmadian M, & Hei SS (2008). Identification and functional characterization of adipose-specific phospholipase A2 (AdPLA). *Journal of Biological Chemistry*, 283(37), 25428–25436. 10.1074/jbc.M804146200 [PubMed: 18614531]
- Engel LA, Sun M, Jing Z, O'Brien DE, & Kotzbauer PT (2010). Catalytic Function of PLA2G6 Is Impaired by Mutations Associated with Infantile Neuroaxonal Dystrophy but Not Dystonia-Parkinsonism. *PLoS ONE*, 5(9), e12897. 10.1371/journal.pone.0012897
- Funk CD (2001). Prostaglandins and leukotrienes: Advances in eicosanoid biology. *Science*, 294(5548), 1871–1875. 10.1126/science.294.5548.1871 [PubMed: 11729303]
- Gaposchkin DP, Farber HW, & Zoeller RA (2008). On the importance of plasmalogen status in stimulated arachidonic acid release in the macrophage cell line RAW 264.7. *Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids*, 1781(4). 10.1016/j.bbalip.2008.01.007
- Gil-de-Gómez L, Astudillo AM, Guijas C, Magrioti V, Kokotos G, Balboa MA, & Balsinde J. (2014). Cytosolic Group IVA and Calcium-Independent Group VIA Phospholipase A2 s Act on Distinct Phospholipid Pools in Zymosan-Stimulated Mouse Peritoneal Macrophages. *The Journal of Immunology*, 192(2), 752–762. 10.4049/jimmunol.1302267 [PubMed: 24337743]
- Gross RW, Ramanaidam S, Kruszka KK, Han X, & Turk J. (1993). Rat and Human Pancreatic Islet Cells Contain a Calcium Ion Independent Phospholipase A2 Activity Selective for Hydrolysis of Arachidonate Which Is Stimulated by Adenosine Triphosphate and Is Specifically Localized to Islet β -Cells. *Biochemistry*, 32(1). 10.1021/bi00052a041
- Guo YP, Tang BS, & Guo JF (2018). PLA2G6-Associated Neurodegeneration (PLAN): Review of Clinical Phenotypes and Genotypes. In *Frontiers in Neurology* (Vol. 9). 10.3389/fneur.2018.01100
- Hanks SK, Quinn AM, & Hunter T. (1988). The protein kinase family: Conserved features and deduced phylogeny of the catalytic domains. *Science*, 241(4861). 10.1126/science.3291115
- Hayashi D, Mouchlis VD, & Dennis EA (2021). Omega-3 Versus Omega-6 Fatty Acid Availability is Controlled by Hydrophobic Site Geometries of Phospholipase A2s. *Journal of Lipid Research*, 100113. 10.1016/j.jlr.2021.100113
- Hayashi D, Mouchlis VD, & Dennis EA (2022). Each phospholipase A2 type exhibits distinct selectivity toward sn-1 ester, alkyl ether, and vinyl ether phospholipids. *Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids*, 1867(1). 10.1016/j.bbalip.2021.159067
- Hossain MS, Mineno K, & Katafuchi T. (2016). Neuronal orphan G-protein coupled receptor proteins mediate plasmalogens-induced activation of ERK and Akt signaling. *PLoS ONE*, 11(3), 1–14. 10.1371/journal.pone.0150846
- Hsu YH, Burke JE, Li S, Woods VL, & Dennis EA (2009). Localizing the membrane binding region of group VIA Ca²⁺-independent phospholipase A2 using peptide amide hydrogen/deuterium exchange mass spectrometry. *Journal of Biological Chemistry*, 284(35), 23652–23661. 10.1074/jbc.M109.021857 [PubMed: 19556238]

- Hsu YH, Dumlao DS, Cao J, & Dennis EA (2013). Assessing Phospholipase A2 Activity toward Cardiolipin by Mass Spectrometry. *PLoS ONE*, 8(3). 10.1371/journal.pone.0059267
- Jenkins CM, Han X, Mancuso DJ, & Gross RW (2002). Identification of calcium-independent phospholipase A2 (iPLA2) β , and not iPLA2 γ , as the mediator of arginine vasopressin-induced arachidonic acid release in A-10 smooth muscle cells. Enantioselective mechanism-based discrimination of mammalian iPLA2s. *Journal of Biological Chemistry*, 277(36). 10.1074/jbc.M202568200
- Jenkins CM, Wolf MJ, Mancuso DJ, & Gross RW (2001). Identification of the calmodulin-binding domain of recombinant calcium-independent phospholipase A2 β . Implications for structure and function. *Journal of Biological Chemistry*, 276(10), 7129–7135. 10.1074/jbc.M010439200 [PubMed: 11118454]
- Jenkins CM, Yan W, Mancuso DJ, & Gross RW (2006). Highly selective hydrolysis of fatty acyl-CoAs by calcium-independent phospholipase A2 β : Enzyme autoacylation and acyl-CoA-mediated reversal of calmodulin inhibition of phospholipase A2 activity. *Journal of Biological Chemistry*, 281(23). 10.1074/jbc.M511623200
- Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates R, Žídek A, Potapenko A, Bridgland A, Meyer C, Kohl SAA, Ballard AJ, Cowie A, Romera-Paredes B, Nikolov S, Jain R, Adler J, ... Hassabis D. (2021). Highly accurate protein structure prediction with AlphaFold. *Nature*, 596(7873), 583–589. 10.1038/s41586-021-03819-2 [PubMed: 34265844]
- Ke M, Chong CM, Zeng H, Huang M, Huang Z, Zhang K, Cen X, Lu JH, Yao X, Qin D, & Su H. (2020). Azoramide protects iPSC-derived dopaminergic neurons with PLA2G6 D331Y mutation through restoring ER function and CREB signaling. *Cell Death and Disease*, 11(2). 10.1038/s41419-020-2312-8
- Kienesberger PC, Oberer M, Lass A, & Zechner R. (2009). Mammalian patatin domain containing proteins: A family with diverse lipolytic activities involved in multiple biological functions. *Journal of Lipid Research*, 50(SUPPL.), 63–68. 10.1194/jlr.R800082-JLR200
- Kinghorn KJ, Castillo-Quan JI, Bartolome F, Angelova PR, Li L, Pope S, Cochemé HM, Khan S, Asghari S, Bhatia KP, Hardy J, Abramov AY, & Partridge L. (2015). Loss of PLA2G6 leads to elevated mitochondrial lipid peroxidation and mitochondrial dysfunction. *Brain*, 138(7), 1801–1816. 10.1093/brain/awv132 [PubMed: 26001724]
- Komljenovic D, Sandhoff R, Teigler A, Heid H, Just WW, & Gorgas K. (2009). Disruption of blood-testis barrier dynamics in ether-lipid-deficient mice. *Cell and Tissue Research*, 337(2), 281–299. 10.1007/s00441-009-0809-7 [PubMed: 19495798]
- Kono N, & Arai H. (2019). Platelet-activating factor acetylhydrolases: An overview and update. *Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids*, 1864(6), 922–931. 10.1016/j.bbalip.2018.07.006 [PubMed: 30055287]
- Lands WEM (1957). Metabolism of glycerophospholipids: A comparison of lecithin and triglyceride synthesis. *Journal of Biological Chemistry*, 231, 883–888.
- Larsson Forsell PKA, Kennedy BP, & Claesson HE (1999). The human calcium-independent phospholipase A2 gene: Multiple enzymes with distinct properties from a single gene. *European Journal of Biochemistry*. 10.1046/j.1432-1327.1999.00418.x
- Larsson PKA, Claesson HE, & Kennedy BP (1998). Multiple splice variants of the human calcium-independent phospholipase A2 and their effect on enzyme activity. *Journal of Biological Chemistry*, 273(1), 207–214. 10.1074/jbc.273.1.207 [PubMed: 9417066]
- Lei X, Bone RN, Ali T, Zhang S, Bohrer A, Tse HM, Bidasee KR, & Ramanadham S. (2014). Evidence of contribution of iPLA2 β -mediated events during islet β -cell apoptosis due to proinflammatory cytokines suggests a role for iPLA2 β in T1D development. *Endocrinology (United States)*, 155(9). 10.1210/en.2013-2134
- Lei X, Zhang S, Barbour SE, Bohrer A, Ford EL, Koizumi A, Papa FR, & Ramanadham S. (2010). Spontaneous development of endoplasmic reticulum stress that can lead to diabetes mellitus is associated with higher calcium-independent phospholipase A2 expression: A role for regulation by SREBP-1. *Journal of Biological Chemistry*, 285(9). 10.1074/jbc.M109.084293
- Leslie CC (2015). Cytosolic phospholipase A2: Physiological function and role in disease. *Journal of Lipid Research*, 56(8), 1386–1402. 10.1194/jlr.R057588 [PubMed: 25838312]

- Lio YC, & Dennis EA (1998). Interfacial activation, lysophospholipase and transacylase activity of Group VI Ca²⁺-independent phospholipase A2. *Biochimica et Biophysica Acta - Lipids and Lipid Metabolism*. 10.1016/S0005-2760(98)00049-6
- Lord CC, Thomas G, & Brown JM (2013). Mammalian alpha beta hydrolase domain (ABHD) proteins: Lipid metabolizing enzymes at the interface of cell signaling and energy metabolism. In *Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids* (Vol. 1831, Issue 4, pp. 792–802). 10.1016/j.bbali.2013.01.002
- Lu CS, Lai SC, Wu RM, Weng YH, Huang CL, Chen RS, Chang HC, Wu-Chou YH, & Yeh TH (2012). PLA2G6 mutations in PARK14-linked young-onset parkinsonism and sporadic Parkinson's disease. *American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics*, 159 B(2), 183–191. 10.1002/ajmg.b.32012
- Ma Z, Wang X, Nowatzke W, Ramanadham S, & Turk J. (1999). Human pancreatic islets express mRNA species encoding two distinct catalytically active isoforms of group VI phospholipase A2 (iPLA2) that arise from an exon-skipping mechanism of alternative splicing of the transcript from the iPLA2 gene on chromosome 22q13.1. *Journal of Biological Chemistry*, 274(14), 9607–9616. 10.1074/jbc.274.14.9607 [PubMed: 10092647]
- Mahul-Mellier AL, Burtcher J, Maharjan N, Weerens L, Croisier M, Kuttler F, Leleu M, Knott GW, & Lashuel HA (2020). The process of Lewy body formation, rather than simply α -synuclein fibrillization, is one of the major drivers of neurodegeneration. *Proceedings of the National Academy of Sciences of the United States of America*, 117(9). 10.1073/pnas.1913904117
- Malhotra A, Edelman-Novemsky I, Xu Y, Plesken H, Ma J, Schlame M, & Ren M. (2009). Role of calcium-independent phospholipase A2 in the pathogenesis of Barth syndrome. *Proceedings of the National Academy of Sciences of the United States of America*. 10.1073/pnas.0811224106
- Malik I, Turk J, Mancuso DJ, Montier L, Wohltmann M, Wozniak DF, Schmidt RE, Gross RW, & Kotzbauer PT (2008). Disrupted membrane homeostasis and accumulation of ubiquitinated proteins in a mouse model of infantile neuroaxonal dystrophy caused by PLA2G6 mutations. *American Journal of Pathology*, 172(2), 406–416. 10.2353/ajpath.2008.070823 [PubMed: 18202189]
- Malley KR, Koroleva O, Miller I, Sanishvili R, Jenkins CM, Gross RW, & Korolev S. (2018). The structure of iPLA2 β reveals dimeric active sites and suggests mechanisms of regulation and localization. *Nature Communications*, 9(1), 1–11. 10.1038/s41467-018-03193-0
- Mancuso DJ, Jenkins CM, & Gross RW (2000). The genomic organization, complete mRNA sequence, cloning, and expression of a novel human intracellular membrane-associated calcium-independent phospholipase A2. *Journal of Biological Chemistry*, 275(14). 10.1074/jbc.275.14.9937
- Mancuso DJ, Kotzbauer P, Wozniak DF, Sims HF, Jenkins CM, Guan S, Han X, Yang K, Sun G, Malik I, Conyers S, Green KG, Schmidt RE, & Gross RW (2009). Genetic ablation of calcium-independent phospholipase A2 γ leads to alterations in hippocampal cardiolipin content and molecular species distribution, mitochondrial degeneration, autophagy, and cognitive dysfunction. *Journal of Biological Chemistry*, 284(51). 10.1074/jbc.M109.055194
- Manson A, Winter T, & Aukema HM (2023). Phospholipase A2 enzymes differently impact PUFA release and oxylipin formation ex vivo in rat hearts. *Prostaglandins Leukotrienes and Essential Fatty Acids*, 191. 10.1016/j.plefa.2023.102555
- Matys V, Kel-Margoulis O. v., Fricke E, Liebich I, Land S, Barre-Dirrie A, Reuter I, Chekmenev D, Krull M, Hornischer K, Voss N, Stegmaier P, Lewicki-Potapov B, Saxel H, Kel AE, & Wingender E. (2006). TRANSFAC and its module TRANSCOMP: transcriptional gene regulation in eukaryotes. *Nucleic Acids Research*, 34(Database issue). 10.1093/nar/gkj143
- Molloy GY, Rattray M, & Williams RJ (1998). Genes encoding multiple forms of phospholipase A2 are expressed in rat brain. *Neuroscience Letters*, 258(3). 10.1016/S03043-940(98)00838-6
- Morgan N. v., Westaway SK, Morton JEV, Gregory A, Gissen P, Sonek S, Cangul H, Coryell J, Canham N, Nardocci N, Zorzi G, Pasha S, Rodriguez D, Desguerre I, Mubaidin A, Bertini E, Trembath RC, Simonati A, Schanen C, ... Hayflick SJ (2006). PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. *Nature Genetics*. 10.1038/ng1826
- Mori A, Hatano T, Inoshita T, Shiba-Fukushima K, Koinuma T, Meng H, Kubo, Spratt S, Cui C, Yamashita C, Miki Y, Yamamoto K, Hirabayashi T, Murakami M, Takahashi Y, Shindou


- H, Nonaka T, Hasegawa M, Okuzumi A, ... Hattori N. (2019). Parkinson's disease-associated iPLA2-VIA/PLA2G6 regulates neuronal functions and α -synuclein stability through membrane remodeling. *Proceedings of the National Academy of Sciences of the United States of America*, 116(41), 20689–20699. 10.1073/pnas.1902958116 [PubMed: 31548400]
- Mouchlis VD, Bucher D, McCammon JA, & Dennis EA (2015). Membranes serve as allosteric activators of phospholipase A2, enabling it to extract, bind, and hydrolyze phospholipid substrates. *Proceedings of the National Academy of Sciences of the United States of America*, 112(6), E516–E525. 10.1073/pnas.1424651112 [PubMed: 25624474]
- Mouchlis VD, Chen Y, Andrew McCammon J, & Dennis EA (2018). Membrane Allosterity and Unique Hydrophobic Sites Promote Enzyme Substrate Specificity. *Journal of the American Chemical Society*, 140(9), 3285–3291. 10.1021/jacs.7b12045 [PubMed: 29342349]
- Mouchlis VD, & Dennis EA (2022). Membrane Association Allosterically Regulates Phospholipase A 2 Enzymes and Their Specificity. *Accounts of Chemical Research*. 10.1021/acs.accounts.2c00497
- Murakami M. (2017). Lipoquality control by phospholipase A2 enzymes. In *Proceedings of the Japan Academy Series B: Physical and Biological Sciences* (Vol. 93, Issue 9, pp. 677–702). Japan Academy. 10.2183/pjab.93.043 [PubMed: 29129849]
- Murakami M. (2019). Novel functions of phospholipase A 2 s: Overview. In *Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids* (Vol. 1864, Issue 6, pp. 763–765). Elsevier B.V. 10.1016/j.bbalip.2019.02.005 [PubMed: 30769093]
- Murakami M, Masuda S, Ueda-Semmyo K, Yoda E, Kuwata H, Takanezawa Y, Aoki J, Arai H, Sumimoto H, Ishikawa Y, Ishii T, Nakatani Y, & Kudo I. (2005). Group VIB Ca²⁺-independent phospholipase A2 γ promotes cellular membrane hydrolysis and prostaglandin production in a manner distinct from other intracellular phospholipases A2. *Journal of Biological Chemistry*, 280(14), 14028–14041. 10.1074/jbc.M413766200 [PubMed: 15695510]
- Murakami M, Sato H, Miki Y, Yamamoto K, & Taketomi Y. (2015). A new era of secreted phospholipase A2. *Journal of Lipid Research*, 56(7), 1248–1261. 10.1194/jlr.R058123 [PubMed: 25805806]
- Paisán-Ruiz C, Bhatia KP, Li A, Hernandez D, Davis M, Wood NW, Hardy J, Houlden H, Singleton A, & Schneider SA (2009). Characterization of PLA2G6 as a locus for dystonia-parkinsonism. *Annals of Neurology*, 65(1). 10.1002/ana.21415
- Paisán-Ruiz C, Li A, Schneider SA, Holton JL, Johnson R, Kidd D, Chataway J, Bhatia KP, Lees AJ, Hardy J, Revesz T, & Houlden H. (2012). Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations. *Neurobiology of Aging*, 33(4), 814–823. 10.1016/j.neurobiolaging.2010.05.009 [PubMed: 20619503]
- Pérez-Chacón G, Astudillo AM, Balgoma D, Balboa MA, & Balsinde J. (2009). Control of free arachidonic acid levels by phospholipases A2 and lysophospholipid acyltransferases. *Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids*, 1791(12), 1103–1113. 10.1016/j.bbalip.2009.08.007
- Pike LJ, Han X, Chung KN, & Gross RW (2002). Lipid rafts are enriched in arachidonic acid and plasmenylethanolamine and their composition is independent of caveolin-1 expression: A quantitative electrospray ionization/mass spectrometric analysis. *Biochemistry*, 41(6), 2075–2088. 10.1021/bi0156557 [PubMed: 11827555]
- Ramanadham S, Hsu FF, Zhang S, Jin C, Bohrer A, Song H, Bao S, Ma Z, & Turk J. (2004). Apoptosis of Insulin-Secreting Cells Induced by Endoplasmic Reticulum Stress Is Amplified by Overexpression of Group VIA Calcium-Independent Phospholipase A2 (iPLA2 β) and Suppressed by Inhibition of iPLA2 β . *Biochemistry*, 43(4). 10.1021/bi035536m
- Ramanadham S, Song H, Hsu FF, Zhang S, Crankshaw M, Grant GA, Newgard CB, Bao S, Ma Z, & Turk J. (2003). Pancreatic Islets and Insulinoma Cells Express a Novel Isoform of Group VIA Phospholipase A2 (iPLA2 β) that Participates in Glucose-Stimulated Insulin Secretion and Is Not Produced by Alternate Splicing of the iPLA2 β Transcript. *Biochemistry*, 42(47). 10.1021/bi034843p
- Ramanadham S, Tomader A, Ashley JW, Bone RN, Hancock WD, & Lei X. (2015). Calcium-independent phospholipases A2 and their roles in biological processes and diseases. *Journal of Lipid Research*, 56(9), 1643–1668. 10.1194/jlr.R058701 [PubMed: 26023050]

- Rodemer C, Thai TP, Brugger B, Kaercher T, Werner H, Nave KA, Wieland F, Gorgas K, & Just WW (2003). Inactivation of ether lipid biosynthesis causes male infertility, defects in eye development and optic nerve hypoplasia in mice. *Human Molecular Genetics*, 12(15), 1881–1895. 10.1093/hmg/ddg191 [PubMed: 12874108]
- Rydell TJ, Williams JM, Krieger E, Moshiri F, Stallings WC, Brown SM, Pershing JC, Purcell JP, & Alibhai MF (2003). The crystal structure, mutagenesis, and activity studies reveal that patatin is a lipid acyl hydrolase with a Ser-Asp catalytic dyad. *Biochemistry*. 10.1021/bi027156r
- Serhan CN (2007). Resolution Phase of Inflammation: Novel Endogenous Anti-Inflammatory and Proresolving Lipid Mediators and Pathways. *Annual Review of Immunology*, 25(1), 101–137. 10.1146/annurev.immunol.25.022106.141647
- Shayman JA, & Tesmer JGG (2019). Lysosomal phospholipase A2. *Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids*, 1864(6), 932–940. 10.1016/j.bbalip.2018.07.012 [PubMed: 30077006]
- Shi CH, Tang BS, Wang L, Lv ZY, Wang J, Luo LZ, Shen L, Jiang H, Yan XX, Pan Q, Xia K, & Guo JF (2011). PLA2G6 gene mutation in autosomal recessive early-onset parkinsonism in a Chinese cohort. *Neurology*, 77(1). 10.1212/WNL.0b013e318221acd3
- Shindou H, & Shimizu T. (2009). Acyl-CoA:lysophospholipid acyltransferases. *Journal of Biological Chemistry*, 284(1), 1–5. 10.1074/jbc.R800046200 [PubMed: 18718904]
- Shinzawa K, Sumi H, Ikawa M, Matsuoka Y, Okabe M, Sakoda S, & Tsujimoto Y. (2008). Neuroaxonal dystrophy caused by group VIA phospholipase A2 deficiency in mice: A model of human neurodegenerative disease. *Journal of Neuroscience*, 28(9). 10.1523/JNEUROSCI.4354-07.2008
- Sina F, Shojaee S, Elahi E, & Paisán-Ruiz C. (2009). R632W mutation in PLA2G6 segregates with dystonia-parkinsonism in a consanguineous Iranian family. *European Journal of Neurology*. 10.1111/j.1468-1331.2008.02356.x
- Song H, Bao S, Lei X, Jin C, Zhang S, Turk J, & Ramanadham S. (2010). Evidence for proteolytic processing and stimulated organelle redistribution of iPLA2 β . *Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids*, 1081(5), 547–558. 10.1016/j.bbalip.2010.01.006
- Song H, Bao S, Ramanadham S, & Turk J. (2006). Effects of biological oxidants on the catalytic activity and structure of group VIA phospholipase A2. *Biochemistry*. 10.1021/bi060502a
- Song H, Rohrs H, Tan M, Wohltmann M, Ladenson JH, & Turk J. (2010). Effects of endoplasmic reticulum stress on group VIA phospholipase A2 in beta cells include tyrosine phosphorylation and increased association with calnexin. *Journal of Biological Chemistry*, 285(44), 33843–33857. 10.1074/jbc.M110.153197 [PubMed: 20732873]
- Sun GY, Simonyi A, Fritsche KL, Chuang DY, Hannink M, Gu Z, Greenlief CM, Yao JK, Lee JC, & Beversdorf DQ (2018). Docosahexaenoic acid (DHA): An essential nutrient and a nutraceutical for brain health and diseases. In *Prostaglandins Leukotrienes and Essential Fatty Acids* (Vol. 136). 10.1016/j.plefa.2017.03.006
- Sun WY, Tyurin VA, Mikulska-Ruminska K, Shrivastava IH, Anthonymuthu TS, Zhai YJ, Pan MH, Gong HB, Lu DH, Sun J, Duan WJ, Korolev S, Abramov AY, Angelova PR, Miller I, Beharier O, Mao GW, Dar HH, Kapralov AA, ... Kagan VE (2021). Phospholipase iPLA2 β averts ferroptosis by eliminating a redox lipid death signal. *Nature Chemical Biology*, 17(4), 465–476. 10.1038/s41589-020-00734-x [PubMed: 33542532]
- Takagi Y, Nishikado S, Omi J, & Aoki J. (2022). The Many Roles of Lysophospholipid Mediators and Japanese Contributions to This Field. *Biological and Pharmaceutical Bulletin*, 45(8), 1008–1021. 10.1248/bpb.b22-00304 [PubMed: 35908884]
- Tan ST, Ramesh T, Toh XR, & Nguyen LN (2020). Emerging roles of lysophospholipids in health and disease. *Progress in Lipid Research*, 80(October). 10.1016/j.plipres.2020.101068
- Tang J, Kriz RW, Wolfman N, Shaffer M, Seehra J, & Jones SS (1997). A novel cytosolic calcium-independent phospholipase A2 contains eight ankyrin motifs. *Journal of Biological Chemistry*, 272(13), 8567–8575. 10.1074/jbc.272.13.8567 [PubMed: 9079687]
- Teigler A, Komljenovic D, Draguhn A, Gorgas K, & Just WW (2009). Defects in myelination, paranode organization and Purkinje cell innervation in the ether lipid-deficient mouse


cerebellum. *Human Molecular Genetics*, 18(11), 1897–1908. 10.1093/hmg/ddp110 [PubMed: 19270340]

- Tomiyama H, Yoshino H, Ogaki K, Li L, Yamashita C, Li Y, Funayama M, Sasaki R, Kokubo Y, Kuzuhara S, & Hattori N. (2011). PLA2G6 variant in Parkinson's disease. *Journal of Human Genetics*, 56(5). 10.1038/jhg.2011.22
- Tsukahara T, Tsukahara R, Yasuda S, Makarova N, Valentine WJ, Allison P, Yuan H, Baker DL, Li Z, Bittman R, Parrill A, & Tigyi G. (2006). Different residues mediate recognition of 1-O-oleyl-lysophosphatidic acid and rosiglitazone in the ligand binding domain of peroxisome proliferator-activated receptor. *Journal of Biological Chemistry*, 281(6), 3398–3407. 10.1074/jbc.M510843200 [PubMed: 16321982]
- Varadi M, Anyango S, Deshpande M, Nair S, Natassia C, Yordanova G, Yuan D, Stroe O, Wood G, Laydon A, Zidek A, Green T, Tunyasuvunakool K, Petersen S, Jumper J, Clancy E, Green R, Vora A, Lutfi M, ... Velankar S. (2022). AlphaFold Protein Structure Database: Massively expanding the structural coverage of protein-sequence space with high-accuracy models. *Nucleic Acids Research*, 50(D1), D439–D444. 10.1093/nar/gkab1061 [PubMed: 34791371]
- Wada H, Yasuda T, Miura I, Watabe K, Sawa C, Kamijuku H, Kojo S, Taniguchi M, Nishino I, Wakana S, Yoshida H, & Seino KI (2009). Establishment of an improved mouse model for infantile neuroaxonal dystrophy that shows early disease onset and bears a point mutation in Pla2g6. *American Journal of Pathology*, 175(6), 2257–2263. 10.2353/ajpath.2009.090343 [PubMed: 19893029]
- Wang Z, Ramanadham S, Ma ZA, Bao S, Mancuso DJ, Gross RW, & Turk J. (2005). Group VIA phospholipase A2 forms a signaling complex with the calcium/calmodulin-dependent protein kinase II β expressed in pancreatic islet β -cells. *Journal of Biological Chemistry*, 280(8). 10.1074/jbc.M405287200
- Willenberg I, Ostermann AI, & Schebb NH (2015). Targeted metabolomics of the arachidonic acid cascade: current state and challenges of LC-MS analysis of oxylipins. *Analytical and Bioanalytical Chemistry*, 407(10). 10.1007/s00216-014-8369-4
- Winstead M. v., Balsinde J, & Dennis EA (2000). Calcium-independent phospholipase A2: Structure and function. In *Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids* (Vol. 1488, Issues 1–2). 10.1016/S1388-1981(00)00107-4
- Wolf MJ, & Gross RW (1996). The calcium-dependent association and functional coupling of calmodulin with myocardial phospholipase A2. Implications for cardiac cycle-dependent alterations in phospholipolysis. *Journal of Biological Chemistry*. 10.1074/jbc.271.35.20989
- Yamashita A, Hayashi Y, Nemoto-Sasaki Y, Ito M, Oka S, Tanikawa T, Waku K, & Sugiura T. (2014). Acyltransferases and transacylases that determine the fatty acid composition of glycerolipids and the metabolism of bioactive lipid mediators in mammalian cells and model organisms. *Progress in Lipid Research*, 53(1), 18–81. 10.1016/j.plipres.2013.10.001 [PubMed: 24125941]
- Yan W, Jenkins CM, Han X, Mancuso DJ, Sims HF, Yang K, & Gross RW (2005). The highly selective production of 2-arachidonoyl lysophosphatidylcholine catalyzed by purified calcium-independent phospholipase A2 γ : Identification of a novel enzymatic mediator for the generation of a key branch point intermediate in eicosanoid signaling. *Journal of Biological Chemistry*, 280(29). 10.1074/jbc.M502358200
- Yeh TH, Liu HF, Chiu CC, Cheng ML, Huang GJ, Huang YC, Liu YC, Huang YZ, Lu CS, Chen YC, Chen HY, & Cheng YC (2021). PLA2G6 mutations cause motor dysfunction phenotypes of young-onset dystonia–parkinsonism type 14 and can be relieved by DHA treatment in animal models. *Experimental Neurology*, 346. 10.1016/j.expneurol.2021.113863
- Yoshino H, Tomiyama H, Tachibana N, Ogaki K, Li Y, Funayama M, Hashimoto T, Takashima S, & Hattori N. (2010). Phenotypic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism. *Neurology*, 75(15). 10.1212/WNL.0b013e3181f73649


R¹: *sn*-1 carbon chain
 R²: *sn*-2 carbon chain




X: head groups




Phosphatidylcholine (PC)




Phosphatidylethanolamine (PE)




Phosphatidic acid (PA)



Phosphatidylglycerol (PG)




Phosphatidylserine (PS)




Phosphatidylinositol (PI)


sn-1 linkage



Ester



Alkyl ether



Vinyl ether

Fig. 1. Enzymatic action of PLA₂ on a variety of glycerophospholipid structures.

Note that phosphatidylinositol (PI) can contain one or more phosphates on each of the inositol backbone positions shown giving rise to numerous additional molecular species.




Fig. 2. Structure of GVIA iPLA₂.

(A) Schematic presentation of major GVIA iPLA₂ splicing variants. (B) X-ray crystal structure of short isoform of GVIA iPLA₂ dimer with 3.95 Å resolution from (Malley et al., 2018) (Protein Data Bank (PDB) ID: 6AUN). (C) Homology model of the catalytic domain of GVIA iPLA₂ reproduced from (Mouchlis et al., 2015).




Fig. 3. Substrate specificity of GVIA iPLA₂.

(A) Optimal binding mode of *sn*-2 acyl chains of 16:0/14:0 PC (pink) and 16:0/18:2 PC (green) in the hydrophobic subsites of GVIA iPLA₂ (cyan surface) after 1 μsec MD simulation. Pink and green dashed lines indicate hydrophobic pockets for *sn*-2 14:0 and 18:1 chains, respectively. The image was newly generated based on the result previously reported (Mouchlis et al., 2018). (B) The substrate specificity of GVIA-2 iPLA₂ toward *sn*-2 AA, EPA, and DHA in an equal molar mixture of 16:0/20:4 PE, 16:0/20:5 PE, and 16:0/22:6 PE. (C) Optimal binding mode of *sn*-2 EPA chain in the hydrophobic subsite of GVIA iPLA₂ after 1 μsec MD simulation. The image was newly generated based on the result previously reported (Hayashi et al., 2021). (D) The activity of GVIA iPLA₂ toward *sn*-1 alkyl ether or ester 16:0 *sn*-2 X PC, where X is 2:0, 18:1, or 20:4 (left panel) and *sn*-1 vinyl ether or ester C18 *sn*-2 X PC, where X is 18:1, 20:4, or 22:6 (right panel). The figures are adapted from our previous report (Hayashi et al., 2022). (E) Hydrogen-bonding interaction between Lys729 and *sn*-1 ester linkage of 16:0/18:2 PC in the GVIA iPLA₂ active site. The image was newly generated based on the result previously reported (Mouchlis et al., 2015).

GVIA iPLA₂ (PDB ID: 6AUN)
GVIB iPLA₂ (AlphaFold)




Fig. 4. Alignment of the three-dimensional structure of the GVIA and GVIB iPLA₂ catalytic domain.

Crystal structure of GVIA iPLA₂ (PDB ID: 6AUN, cyan) and AlphaFold-predicted structure of GVIB iPLA₂ (purple) were aligned.




Fig. 5. Schematic illustration of the relationship between mutations in the *PLA2G6* gene and PLAN diseases.